Sio Capital Management’s Gyre Therapeutics GYRE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
– Sell
-41,593
Closed -$2.56M – 73
2021
Q3
$2.56M Hold
41,593
– – 0.82% 36
2021
Q2
$2.7M Hold
41,593
– – 0.67% 46
2021
Q1
$3.14M Buy
41,593
+29,012
+231% +$2.65M 0.64% 51
2020
Q4
$1.19M Sell
12,581
-667
-5% -$57.8K 0.24% 77
2020
Q3
$854K Hold
13,248
– – 0.17% 76
2020
Q2
$1.17M Sell
13,248
-1,333
-9% -$125K 0.34% 59
2020
Q1
$956K Buy
14,581
+936
+7% +$86K 0.32% 51
2019
Q4
$1.39M Sell
13,645
-1,667
-11% -$140K 0.33% 49
2019
Q3
$1.13M Sell
15,312
-18,991
-55% -$2.05M 0.36% 53
2019
Q2
$3.79M Buy
34,303
+4,016
+13% +$502K 0.91% 41
2019
Q1
$3.68M Buy
30,287
+10,845
+56% +$1.39M 0.99% 45
2018
Q4
$2.3M Sell
19,442
-17,290
-47% -$2.55M 0.84% 45
2018
Q3
$5.94M Buy
36,732
+5,302
+17% +$840K 2.04% 19
2018
Q2
$5.5M Sell
31,430
-45,236
-59% -$15.9M 3.04% 12
2018
Q1
$29.7M Buy
76,666
+63,181
+469% +$23.6M 17.83% 1
2017
Q4
$2.76M Sell
13,485
-14,624
-52% -$1.49M 1.56% 22
2017
Q3
$2.13M Buy
28,109
+4,564
+19% +$274K 1.11% 34
2017
Q2
$1.64M Buy
+23,545
New +$1.69M 0.78% 42

Other funds holding GYRE

Sio Capital Management's GYRE Position: Q4 2021 in Review

Sio Capital Management sold out of Gyre Therapeutics (GYRE) in Q4 2021, closing a stake of 41,593 shares — an estimated $2.56M sold.

Sio Capital Management first reported a position in GYRE in Q2 2017 and held it in 18 quarters. The position peaked at $29.7M in Q1 2018. 51 funds tracked by Wall St. Rank hold GYRE as of Q4 2021.

  • Sio Capital Management reported no remaining Gyre Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Sio Capital Management sold 41,593 Gyre Therapeutics shares in Q4 2021, an estimated $2.56M.
  • Sio Capital Management first reported a position in Gyre Therapeutics in Q2 2017 and held it in 18 quarters.
  • Sio Capital Management's Gyre Therapeutics position peaked at $29.7M in Q1 2018.
  • 51 funds tracked by Wall St. Rank held Gyre Therapeutics as of Q4 2021.

Based on Sio Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.